Blade, Just curious what your strategy is with PRVB in light of the recent developments? I see they have a meeting with the FDA on May 27, which hopefully will clarify things. At these lower levels the stock looks interesting if there can be a timely resolution to the PK/PD issues. But looks like a lot of uncertainty until there is some clarification.
Thanks for any insights.
KZIA also looks like it might be at a good re-entry point, as does ONCT. Any thoughts on these? Thanks.
Fwiw I luckily bailed on all the bio stocks back in Feb/Mar, along with other previously hot/trendy sectors, but some of these are now starting to look cheap. My strategy for the stock allocation is mainly the broad index ETFs (S+P 500), but now those are also looking over-extended. Buy/hold has definitely become more difficult in this market..